SCD1 is found to be overexpressed in many types of cancers, such as breast, ovarian, lung, gastric, colon cancers, hepatocellular carcinoma (HCC) and clear-cell renal cell carcinoma (ccRCC) (30–36), and endows cancers with progressive, invasive and migratory properties, which makes SCD1 a promising anti-cancer target. Here, SCD is linked to hepatocellular carcinoma.